Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $12.57 Consensus PT from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGRGet Rating) has received a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.57.

A number of equities research analysts have recently commented on the stock. Chardan Capital lifted their price target on shares of Voyager Therapeutics from $4.00 to $6.00 in a report on Wednesday, March 9th. StockNews.com assumed coverage on shares of Voyager Therapeutics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a report on Saturday, March 12th. Finally, UBS Group reduced their price target on shares of Voyager Therapeutics from $14.00 to $6.00 in a research report on Monday, January 3rd.

In other news, COO Robin Swartz sold 4,413 shares of the business’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of $8.29, for a total transaction of $36,583.77. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Robert W. Hesslein sold 4,955 shares of the business’s stock in a transaction on Monday, March 21st. The stock was sold at an average price of $8.29, for a total transaction of $41,076.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,933 shares of company stock worth $124,170. 25.40% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Voyager Therapeutics in the fourth quarter valued at $28,000. Marshall Wace LLP acquired a new stake in Voyager Therapeutics in the fourth quarter valued at $1,195,000. Millennium Management LLC raised its holdings in Voyager Therapeutics by 54.8% in the fourth quarter. Millennium Management LLC now owns 423,058 shares of the company’s stock valued at $1,146,000 after acquiring an additional 149,698 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Voyager Therapeutics during the fourth quarter valued at $56,000. Finally, D. E. Shaw & Co. Inc. bought a new stake in Voyager Therapeutics during the fourth quarter valued at $797,000. 63.55% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ VYGR opened at $8.92 on Friday. The company has a market cap of $339.99 million, a PE ratio of -4.69 and a beta of 1.13. Voyager Therapeutics has a 12 month low of $2.46 and a 12 month high of $9.74. The company has a 50-day simple moving average of $6.20 and a 200-day simple moving average of $4.27.

Voyager Therapeutics (NASDAQ:VYGRGet Rating) last issued its quarterly earnings results on Tuesday, March 8th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.51. The business had revenue of $28.07 million during the quarter, compared to the consensus estimate of $31.45 million. Voyager Therapeutics had a negative net margin of 190.30% and a negative return on equity of 66.35%. As a group, analysts expect that Voyager Therapeutics will post -1.35 EPS for the current fiscal year.

About Voyager Therapeutics (Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Recommended Stories

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.